Corcept Therapeutics Incorporated (CORT) is a Biotechnology company in the Healthcare sector, currently trading at $43.68. It has a SharesGrow Score of 77/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CORT = $1,112.99 (+2448.1% from the current price, the stock appears undervalued). Analyst consensus target is CORT = $68 (+56.6% upside).
Valuation: CORT trades at a trailing Price-to-Earnings (P/E) of 44.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.18.
Financials: revenue is $761M, +24.3%/yr average growth. Net income is $100M, growing at +2.5%/yr. Net profit margin is 13.1% (healthy). Gross margin is 98.3% (-0.4 pp trend).
Balance sheet: total debt is $6M against $648M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 2.92 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $837M.
Analyst outlook: 13 / 25 analysts rate CORT as buy (52%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 79/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 66/100 (Partial), Future 64/100 (Pass), Income 55/100 (Partial).
